MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Provide Update on Omicron Variant
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Completes Acquisition of Trillium Therapeutics
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
PFIZER REPORTS THIRD-QUARTER 2021 RESULTS
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
News headline image
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer Declares Fourth-Quarter 2021 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
News headline image
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story